P813: EFFICACY, TREATMENT ADMINISTRATION SATISFACTION AND SAFETY OF SUBCUTANEOUS RAVULIZUMAB THROUGH 1 YEAR IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO RECEIVED PRIOR INTRAVENOUS ECULIZUMAB

• M. N. Yenerel,
• F. Sicre de Fontbrune,
• C. Piatek,
• F. Sahin,
• W. Füreder,
• M. Ogawa,
• I. Tomazos,
• H. Doll,
• A. Ozol-Godfrey,
• J. R. Sierra,
• J. Szer

Affiliations

M. N. Yenerel

1 Division of Hematology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

F. Sicre de Fontbrune

2 Hematology and Bone Marrow Transplant Unit, Assistance Publique Hôpitaux des Paris, Saint Louis Hospital, Paris, France

C. Piatek

3 Jane Anne Nohl Division of Hematology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States of America

F. Sahin

4 Department of Hematology, Ege University Bornova, Izmir, Turkey

W. Füreder

5 Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria

M. Ogawa

6 Alexion, AstraZeneca Rare Disease, Boston, MA, United States of America

I. Tomazos

6 Alexion, AstraZeneca Rare Disease, Boston, MA, United States of America

H. Doll

7 Clinical Outcomes Solutions, Folkstone, United Kingdom

A. Ozol-Godfrey

6 Alexion, AstraZeneca Rare Disease, Boston, MA, United States of America

J. R. Sierra

6 Alexion, AstraZeneca Rare Disease, Boston, MA, United States of America

J. Szer

8 Haematology at Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia